Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) shares fell 0.9% during trading on Friday . The company traded as low as $14.04 and last traded at $14.20, with a volume of 170,564 shares trading hands. The stock had previously closed at $14.33.

A number of research firms recently commented on LXRX. Needham & Company LLC reiterated a “buy” rating on shares of Lexicon Pharmaceuticals in a research note on Thursday, August 11th. Zacks Investment Research lowered shares of Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, August 11th. Stifel Nicolaus raised their price objective on shares of Lexicon Pharmaceuticals from $25.00 to $26.00 and gave the company a “buy” rating in a research note on Friday, August 5th. Wedbush raised their price objective on shares of Lexicon Pharmaceuticals from $30.00 to $31.00 and gave the company an “outperform” rating in a research note on Friday, August 5th. Finally, Citigroup Inc. began coverage on shares of Lexicon Pharmaceuticals in a research note on Tuesday, August 2nd. They set a “buy” rating and a $21.00 price objective on the stock. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and four have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $20.07.

The firm has a 50-day moving average of $15.46 and a 200-day moving average of $13.48. The stock’s market cap is $1.48 billion.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.41) by $0.04. During the same period in the previous year, the firm earned ($0.27) EPS. The business earned $20.10 million during the quarter, compared to the consensus estimate of $12.36 million. The business’s revenue was up 5186.8% compared to the same quarter last year. On average, equities analysts anticipate that Lexicon Pharmaceuticals Inc. will post ($1.54) earnings per share for the current year.

Lexicon Pharmaceuticals, Inc (Lexicon) is a biopharmaceutical company. The Company focuses on the development of treatments for human disease. The Company is engaged in the development of two drug candidates: telotristat etiprate (LX1032) and sotagliflozin (LX4211). The Company’s telotristat etiprate, is an orally delivered small molecule drug candidate, as a treatment for carcinoid syndrome.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.